Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Neurogene (NGNE) over the last 3 years, with Q3 2025 value amounting to -$501000.0.

  • Neurogene's Change in Account Payables fell 162758.62% to -$501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$198000.0, marking a year-over-year increase of 6063.62%. This contributed to the annual value of -$77000.0 for FY2024, which is 11154.42% down from last year.
  • Latest data reveals that Neurogene reported Change in Account Payables of -$501000.0 as of Q3 2025, which was down 162758.62% from -$975000.0 recorded in Q2 2025.
  • Neurogene's 5-year Change in Account Payables high stood at $1.7 million for Q1 2025, and its period low was -$975000.0 during Q2 2025.
  • In the last 3 years, Neurogene's Change in Account Payables had a median value of $27000.0 in 2023 and averaged $73454.5.
  • Within the past 5 years, the most significant YoY rise in Neurogene's Change in Account Payables was 115481.48% (2025), while the steepest drop was 162758.62% (2025).
  • Neurogene's Change in Account Payables (Quarter) stood at -$842000.0 in 2023, then skyrocketed by 50.59% to -$416000.0 in 2024, then fell by 20.43% to -$501000.0 in 2025.
  • Its Change in Account Payables was -$501000.0 in Q3 2025, compared to -$975000.0 in Q2 2025 and $1.7 million in Q1 2025.